|Bid||75.62 x 1300|
|Ask||75.49 x 900|
|Day's range||75.37 - 75.85|
|52-week range||74.09 - 94.26|
|Beta (5Y monthly)||0.49|
|PE ratio (TTM)||7.44|
|Forward dividend & yield||3.33 (4.37%)|
|Ex-dividend date||08 Mar 2022|
|1y target est||102.00|
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Ionis (IONS) posts data from the phase IIb SOLANO study on ION449 for treating hypercholesterolemia. Though the study met the primary endpoint, ION449 will not advance into phase III development.
Novartis (NVS) unveils a new focused strategy with the spotlight on the US markets driven by eight key brands that are expected to have a multi-billion dollar peak sales potential.